TNF and inflammatory bowel disease: However, all patients had significantly higher antibody concentrations 3–9 weeks after the third vaccination than those at the same time point after the initial two vaccine series, regardless of the IBD treatment: anti-TNFα (3–9 weeks after the initial two vaccine series (361 U/mL) vs. 3–9 weeks after the third vaccine dose (4896 U/mL), p < 0.01); non-anti-TNFα including 5-ASA (3–9 weeks after the initial two vaccine series (1223 U/mL) vs. 3–9 weeks after the third vaccine dose (30,900 U/mL), p < 0.01) (Figure 3).